An analysis from Milliman finds the IRA’s drug pricing provisions could undermine the benefits of the new out-of-pocket limit for millions of seniors and people with disabilities. As a direct result of these provisions, 3.5 million Part D patients taking a medicine subject to an MFP could see higher out-of-pocket costs in 2026.